Compare RSSS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | MIST |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 163.2M |
| IPO Year | N/A | N/A |
| Metric | RSSS | MIST |
|---|---|---|
| Price | $2.98 | $2.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $6.33 |
| AVG Volume (30 Days) | 110.0K | ★ 5.3M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $49,325,684.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $73.99 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $2.32 | $0.63 |
| 52 Week High | $4.24 | $3.06 |
| Indicator | RSSS | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 46.58 |
| Support Level | $2.78 | $2.50 |
| Resistance Level | $3.03 | $2.73 |
| Average True Range (ATR) | 0.17 | 0.26 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 36.51 | 48.62 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).